Educational Notice
This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on semaglutide. It is not medical advice, a treatment recommendation, or an endorsement of any specific use. Semaglutide (Ozempic, Wegovy, Rybelsus) is an FDA-approved prescription medication. It should only be obtained and used under the supervision of a licensed healthcare provider. Consult a qualified healthcare professional before making any health or treatment decisions.
BLUF: Bottom Line Up Front
Semaglutide is the drug that changed everything. It’s FDA-approved as Wegovy (weight loss) and Ozempic (diabetes). GLP-1 mimics a natural hormone that tells your brain you’re full. Clinical trials showed average weight loss of 15% of body weight—transformative for many people. Millions have used it. Side effects are well-documented (nausea, GI issues). It works. The trade-off: weekly injection, cost, and long-term data is still accumulating. But this is the proven winner that broke the obesity treatment ceiling.
The once-weekly GLP-1 agonist that rewrote the obesity treatment landscape — what the clinical data actually shows
Semaglutide is the compound that moved glucagon-like peptide-1 receptor agonism from a diabetes medication class into a mainstream obesity treatment. Novo Nordisk’s development of a fatty acid-modified GLP-1 analog with a 7-day half-life solved the fundamental inconvenience problem that limited earlier GLP-1 agonists — daily injections — and opened the door to a once-weekly subcutaneous injection that could be self-administered. The STEP trial program, which began publishing in 2021, produced weight loss data of a magnitude that had never been seen from a pharmacological intervention: ~15% mean body weight reduction versus ~2.4% placebo at 68 weeks. Those numbers changed the clinical conversation about obesity treatment.
The 2023 SELECT trial extended semaglutide’s evidence base in a direction that surprised many observers: a 20% reduction in major adverse cardiovascular events in overweight and obese adults with established CVD but without type 2 diabetes. This was not a weight loss trial; it was a cardiovascular outcomes trial. The FDA approved Wegovy for CV risk reduction in 2024 on the basis of that data. Semaglutide is now the first anti-obesity medication with a demonstrated cardiovascular mortality benefit.
Understanding semaglutide in 2026 requires understanding both what it does and where it stands competitively. Tirzepatide — a dual GLP-1/GIP agonist — has outperformed semaglutide in head-to-head comparison (SURMOUNT-5, 2025) and is widely viewed as the superior weight loss agent in the incretin class. Triple agonists (retatrutide) and other novel mechanisms are advancing through Phase III. Semaglutide is the compound that established the clinical standard for pharmacological obesity treatment. It is not the endpoint.
Table of Contents
- What Is Semaglutide?
- Origins and Development
- Mechanism of Action
- Approved Indications
- Key Research Areas and Studies
- Common Claims versus Current Evidence
- Safety, Risks, and Limitations
- Regulatory and Legal Status
- Approved Clinical Dosing
- Access, Compounding, and Off-Label Context
- Frequently Asked Questions
- Related Compounds: How Semaglutide Compares
- Summary and Key Takeaways
- Selected References
- Further Reading
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyQuick Facts
| Type | Synthetic GLP-1 receptor agonist peptide analog |
| Brand names | Ozempic (T2D, SC weekly); Wegovy (obesity, SC weekly); Rybelsus (T2D, oral daily) |
| Molecular weight | 4113.6 Da |
| Target receptor | GLP-1R (glucagon-like peptide-1 receptor) |
| Mechanism | GLP-1R agonist → insulin secretion, glucagon suppression, gastric emptying delay, central appetite suppression |
| Half-life | ~168 hours (7 days) — enables once-weekly SC dosing |
| Route | Subcutaneous injection (Ozempic/Wegovy) or oral tablet (Rybelsus) |
| Developer | Novo Nordisk (Denmark) |
| FDA approval | Ozempic: 2017 (T2D); Wegovy: 2021 (obesity/overweight with comorbidity); Rybelsus: 2019 (T2D, oral) |
| Cardiovascular approval | Wegovy: 2024 cardiovascular risk reduction in overweight/obese adults with established CVD |
| WADA status | Not prohibited — not on WADA prohibited list |
| Evidence tier | Approved Drug — multiple Phase III RCTs across indications |
| Key trial data | STEP 1 (2021): ~15% body weight loss over 68 weeks vs. ~2.4% placebo; SELECT (2023): 20% CV event reduction |
What Is Semaglutide?
Semaglutide is a synthetic analog of human GLP-1 — a 30-amino acid incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Native GLP-1 has a plasma half-life of approximately 2 minutes, rapidly degraded by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases. Semaglutide addresses this by three modifications: substitution of alanine at position 8 with alpha-aminoisobutyric acid for DPP-4 resistance, attachment of a C18 fatty diacid chain to lysine at position 26 via a linker for albumin binding, and substitution at position 34 (Arg→Lys) to enable the fatty acid attachment.
Plain English
Three molecular modifications turn a hormone that lasts 2 minutes into one that lasts 7 days: one change blocks the enzyme that destroys it, one attaches a fatty chain that hitches a ride on albumin in the blood, and one enables that fatty chain attachment. The result is once-weekly dosing from a molecule the body would otherwise clear in minutes.
The albumin binding extends semaglutide’s half-life to approximately 7 days — a 5,000-fold increase over native GLP-1. This is what makes once-weekly dosing feasible. The same fatty acid modification also enables oral delivery: Rybelsus uses sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) as an absorption enhancer to protect semaglutide from GI degradation and facilitate gastric absorption. Oral bioavailability remains approximately 1%, requiring the specific administration protocol (fasted, 30 minutes before food) to achieve therapeutic plasma concentrations.
Origins and Development
GLP-1’s glucose-lowering and appetite-suppressing properties were characterized in the 1980s and 1990s by multiple groups, most notably Joel Habener’s laboratory at Massachusetts General Hospital and Jens Juul Holst’s group in Copenhagen. The therapeutic potential was clear; the pharmacokinetic liability — a 2-minute plasma half-life — made native GLP-1 clinically impractical.
Novo Nordisk developed liraglutide (approved 2010) as the first once-daily GLP-1 agonist using fatty acid albumin-binding to extend the half-life to 13 hours. Semaglutide was the next iteration: a longer fatty acid chain and improved linker chemistry to achieve a full 7-day half-life. The SUSTAIN trial program established semaglutide’s profile in type 2 diabetes (Ozempic, approved 2017). The STEP program established it for obesity at the higher 2.4 mg dose (Wegovy, approved 2021). The SELECT trial added the cardiovascular outcomes indication in 2024.
Mechanism of Action
Semaglutide binds and activates GLP-1R, a class B GPCR expressed in pancreatic beta cells, alpha cells, the brain, the gut, the heart, and elsewhere. The therapeutic effects derive from activation at multiple sites:
Pancreatic Effects
In pancreatic beta cells, GLP-1R activation increases intracellular cAMP via Gs coupling, potentiating glucose-stimulated insulin secretion. This is glucose-dependent — GLP-1R agonists augment insulin release only when blood glucose is elevated. At euglycemia, they do not stimulate insulin secretion, explaining the low hypoglycemia risk when used without sulfonylureas or insulin. In pancreatic alpha cells, GLP-1R activation suppresses glucagon secretion, reducing hepatic glucose output.
Plain English
Semaglutide boosts insulin only when blood sugar is already elevated—it doesn’t push insulin when levels are normal. That glucose-dependent switch is why the hypoglycemia risk is low when used alone.
Gastric Effects
GLP-1R activation slows gastric emptying, reducing the rate at which ingested nutrients enter the small intestine. This blunts postprandial glucose excursions and contributes to satiety by prolonging gastric distension. The gastric emptying effect attenuates over time with chronic GLP-1R agonism — it is more pronounced acutely than with long-term treatment.
Central Appetite Suppression
GLP-1R is expressed in hypothalamic nuclei (arcuate, paraventricular), the brainstem (area postrema, nucleus tractus solitarius), and on vagal afferents. Central GLP-1R activation reduces food intake through multiple pathways: suppression of orexigenic NPY/AgRP neurons, activation of anorexigenic POMC neurons, and reduction of the reward value of food via limbic system effects. The central mechanism is considered the primary driver of semaglutide’s sustained weight loss in clinical trials — patients consistently report reduced appetite, reduced food cravings, and reduced “food noise.”
Plain English
Semaglutide reduces appetite through two brain mechanisms: it activates satiety neurons in the hypothalamus (the hunger thermostat), and it dampens the reward response to food in regions that process cravings. You feel less hungry and food becomes less compelling.
Cardiovascular Effects
GLP-1R is expressed in cardiac tissue, vascular endothelium, and macrophages. The cardiovascular benefit seen in SELECT (20% MACE reduction) is not fully explained by weight loss or glycemic improvement alone — the timeline of benefit appears earlier than would be expected from weight-loss-mediated CV risk reduction. Direct GLP-1R-mediated effects on endothelial function, inflammation, and cardiac metabolism are active areas of research.
Plain English
Semaglutide’s cardiovascular benefits—shown in SELECT—appear to come from GLP-1 receptors on heart tissue, blood vessels, and immune cells reducing inflammation and plaque buildup, not just from weight loss alone.
The CGM Perspective
Semaglutide’s glucose-dependent insulin secretion mechanism makes it particularly compatible with continuous glucose monitoring. On a CGM, the characteristic semaglutide response is visible: reduced postprandial glucose excursions, lower overall glucose variability, and blunted fasting glucose — without hypoglycemic episodes in the absence of other glucose-lowering medications. The gastric emptying delay also produces a characteristic time-shift in postprandial glucose peaks.
Approved Indications
| Indication | Brand | Approval Year | Key Trial | Notes |
|---|---|---|---|---|
| Type 2 diabetes (glycemic control) | Ozempic 0.5, 1, 2 mg SC weekly | 2017 | SUSTAIN 1–10 series | CV outcomes benefit (SUSTAIN-6) led to cardiovascular risk reduction labeling |
| Obesity / overweight with ≥1 weight-related comorbidity | Wegovy 2.4 mg SC weekly | 2021 | STEP 1–4 | First GLP-1R agonist approved specifically for obesity |
| Type 2 diabetes (oral) | Rybelsus 7, 14 mg oral daily | 2019 | PIONEER 1–10 | First oral GLP-1R agonist; lower weight loss than SC due to bioavailability |
| Cardiovascular risk reduction (overweight/obese adults with CVD, without T2D) | Wegovy 2.4 mg SC weekly | 2024 | SELECT | First anti-obesity medication with demonstrated CV mortality benefit |
Key Research Areas and Studies
STEP Program — Obesity
The STEP (Semaglutide Treatment Effect in People with obesity) program is the foundational evidence base for Wegovy. STEP 1 (N=1961, no T2D): 14.9% mean body weight loss at 68 weeks vs. 2.4% placebo. STEP 2 (N=1210, T2D): 9.6% vs. 3.4% placebo. STEP 3 (intensive behavioral intervention): 16% vs. 5.7%. STEP 4 (withdrawal study): patients re-randomized to placebo regained ~2/3 of lost weight within 1 year, establishing the maintenance requirement.
SELECT — Cardiovascular
SELECT (N=17,604) enrolled overweight or obese adults with established CVD and without T2D. Semaglutide 2.4 mg weekly reduced MACE (CV death, nonfatal MI, nonfatal stroke) by 20% over a mean 3.3 years of follow-up (HR 0.80, 95% CI 0.72–0.90). CV death was reduced by 15%. This trial transformed the semaglutide evidence base and established GLP-1R agonism as a cardioprotective drug class beyond glucose lowering.
SUSTAIN Program — Type 2 Diabetes
The SUSTAIN trials established semaglutide’s profile against comparators including sitagliptin, dulaglutide, exenatide, and insulin glargine. SUSTAIN-6 (cardiovascular outcomes trial in T2D) demonstrated 26% MACE reduction, providing the CV risk reduction labeling for Ozempic.
SURMOUNT-5 — Head-to-Head vs. Tirzepatide
SURMOUNT-5 (published 2025) directly compared semaglutide 2.4 mg weekly versus tirzepatide 10 and 15 mg weekly in obesity. Tirzepatide produced significantly more weight loss at both doses versus semaglutide. This is the first large head-to-head comparison between the two dominant incretin obesity medications and definitively establishes tirzepatide’s weight loss superiority.
Common Claims versus Current Evidence
| Claim | Evidence | Verdict |
|---|---|---|
| Semaglutide produces ~15% weight loss | STEP 1 trial (N=1961): semaglutide 2.4 mg SC weekly produced mean 14.9% body weight reduction at 68 weeks vs. 2.4% placebo. STEP 2 in T2D showed ~10% reduction. These are the largest weight loss results from any non-surgical intervention in a Phase III trial at the time of publication. | Phase III Supported |
| Semaglutide reduces cardiovascular events | SELECT trial (N=17,604): semaglutide 2.4 mg SC weekly reduced major adverse cardiovascular events (MACE) by 20% vs. placebo in overweight/obese adults without T2D but with established CVD. This finding led to the 2024 FDA approval expansion for CV risk reduction. | Phase III Supported |
| Semaglutide is better than tirzepatide for weight loss | Incorrect. Head-to-head SURMOUNT-5 trial (2025) showed tirzepatide produced significantly more weight loss than semaglutide 2.4 mg weekly. Tirzepatide’s dual GLP-1/GIP mechanism appears to confer additional weight loss beyond GLP-1 agonism alone. | False |
| Semaglutide preserves muscle mass during weight loss | Weight loss from semaglutide includes both fat mass and lean mass loss — the ratio is approximately 70–80% fat, 20–30% lean mass, consistent with dietary caloric deficit patterns. This is not meaningfully different from other interventions producing similar caloric deficits. Combining with resistance exercise mitigates lean mass loss. | Partially Misleading |
| Oral semaglutide is equivalent to injectable | Rybelsus (oral semaglutide 14 mg daily) produces meaningful GLP-1R agonism but less weight loss than Wegovy 2.4 mg SC weekly — primarily because oral bioavailability is ~1% and requires specific administration conditions (fasted, with ≤120 mL water, 30 min before any food). The PIONEER trial program confirms oral efficacy for T2D; weight loss magnitude is lower than SC. Not equivalent. | Partially True — Dose Dependent |
| Semaglutide improves sleep apnea | SURMOUNT-OSA (tirzepatide) and ongoing semaglutide sleep apnea studies show improvement in OSA severity correlating with weight loss. Mechanistically sound; semaglutide-specific OSA trial data is emerging. | Emerging Evidence |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklySafety, Risks, and Limitations
Gastrointestinal Adverse Effects
The most common adverse effects of semaglutide are gastrointestinal: nausea (44% Wegovy vs. 16% placebo in STEP 1), vomiting, diarrhea, and constipation. These are most prominent during dose escalation and typically attenuate over weeks to months. Slow titration over 16–20 weeks substantially reduces GI burden. Approximately 7% of participants discontinued Wegovy due to GI adverse effects in STEP 1.
Pancreatitis
GLP-1R agonists carry a class warning for acute pancreatitis. The absolute risk in clinical trials is low (less than 1% in most trials), but pancreatitis can be serious. Semaglutide should be discontinued if pancreatitis is suspected. Patients with a personal or family history of pancreatitis or elevated triglycerides require careful evaluation before use.
Gallbladder Disease
Rapid weight loss of any kind increases gallstone formation risk. In STEP 1, cholelithiasis occurred in 2.6% of semaglutide vs. 1.2% of placebo participants. Gallbladder-related adverse events (including cholecystitis and cholelithiasis) are a recognized risk with semaglutide and other GLP-1R agonists.
Thyroid C-Cell Tumors
GLP-1R is expressed on thyroid C-cells. Rodent studies showed dose-dependent thyroid C-cell tumors with long-duration GLP-1R agonist exposure; this finding carries a black box warning for the entire drug class. Human relevance is uncertain — calcitonin monitoring is recommended in clinical practice. Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.
Muscle Mass Loss
Significant weight loss from semaglutide includes lean mass loss — estimated at 20–30% of total weight lost, consistent with caloric deficit physiology. Resistance exercise substantially mitigates this. The clinical significance of lean mass loss depends on baseline body composition, exercise behavior, and protein intake. This is increasingly recognized as a clinically important consideration in obesity pharmacotherapy.
Rebound Weight Gain
STEP 4 withdrawal data: patients who discontinued semaglutide after 68 weeks of treatment regained approximately two-thirds of lost weight within 12 months. This establishes that semaglutide requires ongoing treatment to maintain weight loss — a characteristic of managing a chronic disease, not a drug failure, but an important patient expectation to set.
Regulatory and Legal Status
Semaglutide is a Schedule — prescription medication in the United States. Ozempic is approved for type 2 diabetes; Wegovy is approved for obesity (BMI ≥30, or ≥27 with at least one weight-related comorbidity) and cardiovascular risk reduction in overweight/obese adults with CVD. Rybelsus is approved for type 2 diabetes.
Compounded semaglutide became widespread during supply shortages of Ozempic and Wegovy (2022–2024). The FDA declared semaglutide shortage resolutions in 2024, triggering compliance timelines for compounding pharmacies. The regulatory status of compounded semaglutide has been in active flux; verify current FDA guidance on 503A and 503B compounding status rather than relying on any fixed statement here.
Semaglutide is not on the WADA prohibited list and is not prohibited in competitive sport.
Approved Clinical Dosing
| Indication | Starting Dose | Titration | Maintenance Dose | Route | Frequency |
|---|---|---|---|---|---|
| Type 2 Diabetes (Ozempic) | 0.25 mg | 0.25 mg × 4 wk → 0.5 mg × 4 wk → 1 mg → max 2 mg | 0.5–2 mg | SC injection (abdomen, thigh, upper arm) | Once weekly |
| Obesity / Overweight with comorbidity (Wegovy) | 0.25 mg | 0.25→0.5→1.0→1.7→2.4 mg, 4 weeks each step | 2.4 mg | SC injection | Once weekly |
| Type 2 Diabetes (Rybelsus oral) | 3 mg | 3 mg × 30 days → 7 mg → 14 mg if needed | 7–14 mg | Oral tablet — fasted, ≤120 mL water, 30 min before food/other medications | Once daily |
| CV Risk Reduction (Wegovy) | 0.25 mg | Same as Wegovy obesity titration | 2.4 mg | SC injection | Once weekly |
Dose Escalation Is Not Optional
The semaglutide titration schedule exists to allow GI tolerance to develop. Skipping dose steps or accelerating titration dramatically increases nausea, vomiting, and discontinuation rates. The 16–20 week titration to maintenance dose is pharmacologically justified, not a commercial convenience.
Access, Compounding, and Off-Label Context
Semaglutide’s cost and insurance coverage in the United States has been a significant access issue. Wegovy list price exceeds $1,300/month; insurance coverage for obesity pharmacotherapy has been inconsistent, improving as employer and government payer policies evolve. Medicare Part D coverage for obesity medications became available in 2024.
Compounded semaglutide—produced by 503A compounding pharmacies and 503B outsourcing facilities during shortage periods—has been widely used as a lower-cost alternative. Compounded products are not FDA-approved formulations and do not carry the manufacturing quality standards of the branded drugs. The FDA has taken enforcement action against some semaglutide compounders for product quality issues, adulteration, and salt-form formulations (semaglutide sodium or acetate rather than the base form used in Ozempic and Wegovy).
Compounded Semaglutide Warning
Compounded semaglutide is not equivalent to Ozempic or Wegovy. Quality, purity, and potency are not regulated to the same standards. The FDA has identified adverse events including hospitalizations associated with compounded semaglutide, sometimes related to dosing errors from differing concentrations. If cost is the issue, discuss with a prescribing provider — patient assistance programs, state programs, and biosimilar timelines (semaglutide patent expiry around 2026–2031 depending on jurisdiction) may provide alternatives.
Frequently Asked Questions
How is Wegovy different from Ozempic?
Same active ingredient (semaglutide), different approved doses and indications. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly; it also has cardiovascular risk reduction labeling in T2D (SUSTAIN-6 data). Wegovy is approved for obesity and cardiovascular risk reduction in overweight/obese adults, at 2.4 mg weekly — the higher dose produces more weight loss than the doses used in diabetes management. They use different injection devices and have different prescribing pathways.
Does semaglutide cause muscle loss?
Yes — significant weight loss of any kind includes lean mass loss, and semaglutide-driven weight loss follows this pattern with approximately 20–30% of weight lost coming from lean tissue. Whether this is clinically meaningful depends on baseline body composition, age, and exercise behavior. Resistance training and adequate protein intake (≥1.2–1.6 g/kg/day) substantially mitigate lean mass loss. This is an active area of clinical research — newer trial designs are specifically studying body composition outcomes with semaglutide combined with exercise protocols.
What happens if you stop semaglutide?
Most patients regain a substantial portion of lost weight — approximately two-thirds within 12 months (STEP 4 data). This reflects the chronic nature of obesity as a disease with neurobiological drivers that semaglutide suppresses rather than cures. Sustained treatment appears necessary for sustained weight maintenance, similar to the treatment model for hypertension or hyperlipidemia.
Is semaglutide safe for people without diabetes or obesity?
Semaglutide is not approved for off-label weight loss in people who do not meet the Wegovy indication (BMI ≥30, or ≥27 with comorbidity). The safety profile in lean, metabolically healthy individuals who do not have excess adiposity has not been studied. Off-label prescribing occurs; the risk-benefit calculation in this population is speculative relative to the approved indication.
Related Compounds: How Semaglutide Compares
| Compound | Target(s) | Class | Route | Weight Loss Data | Approval Status | Evidence Tier | WADA |
|---|---|---|---|---|---|---|---|
| Semaglutide | GLP-1R | GLP-1 agonist | SC weekly or oral daily | ~15% body weight | Approved (Ozempic/Wegovy) | Phase III STEP/SUSTAIN | Not prohibited |
| Tirzepatide | GLP-1R + GIPR | Dual GLP-1/GIP agonist | SC weekly | ~22% body weight | Approved (Mounjaro/Zepbound) | Phase III SURMOUNT | Not prohibited |
| Liraglutide | GLP-1R | GLP-1 agonist | SC daily | ~5–8% body weight | Approved (Victoza/Saxenda) | Phase III SCALE | Not prohibited |
| Retatrutide | GLP-1R + GIPR + GCGR | Triple agonist | SC weekly | ~24% body weight (Phase II) | Phase III (TRIUMPH) | Phase II/III | Not prohibited |
| CagriSema | GLP-1R + AMY1-3 | GLP-1 + amylin | SC weekly | ~22.7% (REDEFINE 1) | Phase III (REDEFINE) | Phase III | Not prohibited |
| Orforglipron | GLP-1R | Non-peptide oral GLP-1R agonist | Oral daily | ~14.7% (Phase III) | Phase III (ATTAIN) | Phase III | Not prohibited |
| Survodutide | GLP-1R + GCGR | Dual GLP-1/glucagon agonist | SC weekly | ~18.7% (Phase II) | Phase II/III | Phase II/III | Not prohibited |
| 5-Amino-1MQ | NNMT inhibition | Small molecule NNMT inhibitor | Oral (research) | Animal models only | Preclinical | Preclinical | Not prohibited |
| AOD-9604 | Beta-adrenergic | hGH fragment, lipolytic | SC | ~Phase III failed | Phase II/III (failed) | Phase II/III | WADA S2 |
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Weight Loss Efficacy | Route | Mechanism Class | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~7 days | FDA-approved (Wegovy, Ozempic) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III) | Subcutaneous injection (weekly) | GLP-1 agonist | Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding |
| Tirzepatide | Synthetic dual GLP-1R/GIPR agonist peptide | GLP-1R / GIPR | ~5 days | FDA-approved (Zepbound, Mounjaro) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III SURMOUNT-3) | Subcutaneous injection (weekly) | Dual GLP-1/GIP agonist | Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism |
| Retatrutide | Synthetic triple GLP-1R/GIPR/GcgR agonist peptide | GLP-1R / GIPR / GcgR | ~5 days | Phase III clinical trials (not yet approved) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase III) | Up to 24% body weight reduction (Phase II) | Subcutaneous injection (weekly) | Triple GLP-1/GIP/glucagon agonist | Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression |
| Liraglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~13 hours | FDA-approved (Saxenda, Victoza) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | ~5–6% body weight reduction (Phase III SCALE) | Subcutaneous injection (daily) | GLP-1 agonist | First GLP-1 agonist approved for weight loss. Daily dosing; shorter half-life than semaglutide |
| Orforglipron | Synthetic selective GLP-1 receptor agonist peptide | GLP-1R | ~11 hours | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 15% body weight reduction (Phase II interim) | Oral (non-peptide-like oral bioavailability) | GLP-1 agonist (oral) | Oral formulation in development. If approved, would offer first oral GLP-1 class agent for weight loss |
| CagriSema | Synthetic fixed-ratio triple agonist (GLP-1/GIP/GcgR + amylin) | GLP-1R / GIPR / AmylinR / GcgR | ~5 days (tirzepatide component) | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 20% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | Quadruple agonist (GLP-1/GIP/amylin/glucagon) | Broadest receptor profile in development. Amylin pathway targets satiety and gastric emptying synergistically |
| Survodutide | Synthetic dual GLP-1R/GcgR agonist peptide | GLP-1R / GcgR | ~3–4 days | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 18% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | GLP-1/glucagon dual agonist | Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists |
| AOD-9604 | Modified fragment of GH (amino acids 177–191) | GH mimetic (fragment-based) | ~2–4 hours | Not FDA-approved | Prohibited — S4 (Class 2 Hormone/Analogs) — as GH analog | Tier 3 — Pilot / Limited Human Data | ~2–3% body weight reduction (limited human data) | Subcutaneous injection | GH C-terminus analog (lipolytic) | Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims |
| 5-Amino-1MQ | Synthetic small molecule quinone metabolite analog | NNMT inhibitor | ~6–8 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | ~5–8% body weight reduction (mouse models only; limited human data) | Oral (small molecule) | NNMT inhibition (NAD+ pathway) | Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published |
| MOTS-c | Synthetic mitochondrial open-reading-frame peptide (13 amino acids) | AMPK activator (AMP-kinase pathway) | ~2–4 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | Modest weight reduction (animal models); no published human trials | Subcutaneous injection | Mitochondrial-derived peptide analog | Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published |
| Tesamorelin | Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification) | GHRH-R | ~26 minutes | FDA-approved (Egrifta for lipodystrophy in HIV) | Prohibited — S2 (GHRH analog) | Tier 1 — Approved Drug | ~2–4% visceral fat reduction (HIV lipodystrophy indication) | Subcutaneous injection (daily) | GHRH analog | Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations |
Summary and Key Takeaways
- Semaglutide is a once-weekly GLP-1R agonist with FDA approval for type 2 diabetes (Ozempic), obesity (Wegovy), and cardiovascular risk reduction in overweight/obese adults with CVD.
- STEP 1 established ~15% mean body weight loss at 68 weeks — the clinical benchmark for pharmacological obesity treatment when published.
- SELECT (2023) demonstrated 20% MACE reduction in overweight/obese adults with CVD, establishing cardiovascular benefit independent of weight loss.
- Tirzepatide (dual GLP-1/GIP) outperforms semaglutide in head-to-head weight loss comparison (SURMOUNT-5, 2025).
- GI adverse effects (nausea, vomiting) are common during titration; slow dose escalation substantially mitigates them.
- Rebound weight gain occurs on discontinuation — sustained treatment is required for sustained weight maintenance.
- Not WADA prohibited. Prescription medication — requires prescriber oversight in all jurisdictions.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklySelected References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. (STEP 1)
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. (SELECT)
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. (SUSTAIN-6)
- Rubino DM, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity. JAMA. 2022;327(2):138–50. (STEP 8)
- Ozempic and Wegovy prescribing information. Novo Nordisk. 2024.
Further Reading
- Tirzepatide article — peptidings.com/peptides/tirzepatide/
- Semaglutide vs. Tirzepatide comparison — peptidings.com/peptides/semaglutide-vs-tirzepatide/
- Retatrutide article — peptidings.com/peptides/retatrutide/
- Weight Loss & Metabolic Peptides Cluster Hub — peptidings.com/peptides/weight-loss-metabolic/
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations.
Semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription medication in the United States and most jurisdictions. It should only be obtained and used under the supervision of a licensed healthcare provider. Obtaining prescription medications without a valid prescription is illegal in most jurisdictions.
All citations link to primary sources where available. Evidence limitations are stated explicitly and not minimized.
← Previous
RetatrutideNext →
Survodutide